Inovio Pharmaceuticals, Inc.
Cancer vaccines targeting MUC16 and uses thereof
Last updated:
Abstract:
Disclosed herein are nucleic acid molecules comprising one or more nucleic acid sequences that encode a modified consensus MUC16 antigen. Vectors, compositions, and vaccines comprising one or more nucleic acid sequences that encode a modified consensus MUC16 antigen are disclosed. Methods of treating a subject with a MUC16-expressing tumor and methods of preventing a MUC16-expressing tumor are disclosed. Modified consensus MUC16 antigen is disclosed.
Status:
Grant
Type:
Utility
Filling date:
13 Dec 2018
Issue date:
1 Feb 2022